Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 11/20 | 0.60 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | TYR | P14679 | 2/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10774506 | 0.85 | ERN1 (0.66) | ERN1TYRTRIM24TRIM33 | |
| SCHEMBL27882685 | 0.83 | ELANE (0.47) | ERN1ELANECA2TYRTRIM24 | |
| SCHEMBL28670923 | 0.78 | ELANE (0.53) | ELANECA2 | |
| SCHEMBL8323656 | 0.77 | ERN1 (0.60) | ERN1ELANECA2TYRTRIM24 | |
| SCHEMBL6665857 | 0.77 | ERN1 (0.60) | ERN1ELANETYRTRIM24TRIM33 | |
| SCHEMBL15791718 | 0.76 | ALDH1A1 (0.44) | ERN1ELANECA2 | |
| SCHEMBL29559365 | 0.75 | ERN1 (1.00) | ERN1CA2TYRTRIM24TRIM33 | |
| SCHEMBL120412 | 0.75 | ERN1 (1.00) | ERN1CA2TYRTRIM24TRIM33 | |
| SCHEMBL4879195 | 0.75 | ERN1 (0.49) | ERN1ELANECA2TYRTRIM24 | |
| SCHEMBL3889158 | 0.75 | ERN1 (0.71) | ERN1TYRTRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242644-A1 | Factor Viia Inhibitor | PHARMACYCLICS, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| EP-1751114-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121102-A2 | FACTOR VIIA INHIBITOR | PHARMACYCLICS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242644-A1 | Factor Viia Inhibitor | F7, F9, F5 | ERN1 1540/4885ELANE 264/4885CA2 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.